|
|
|
|
|
|
|
|
|
|
|
24.09.26 - 16:01
|
Anavex Stockholders Elect All of the Company′s Director Nominees at 2026 Annual Meeting (GlobeNewswire EN)
|
|
|
NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with high unmet medical needs, today announced that, based on the preliminary vote count provided by its proxy solicitor following the Company's 2026 Annual Meeting of Stockholders (“Annual Meeting”), Anavex stockholders have voted to elect all six of its director nominees – Dr. Jiong Ma, Dr. Peter Donhauser, Dr. Axel Paeger, Mr. Gautam Patel, Dr. Adrian Senderowicz and Dr. Claus van der Velden....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
22.05.26 - 14:03
|
Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification (GlobeNewswire EN)
|
|
|
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders, today announced it received an expected delinquency notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 20, 2026. The Notice indicates that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Nasdaq Listing Rule”) as a result of the Company's inability to timely file its Form 10-Q for the quarterly period ended March 31, 2026....
|
|
|
|
|
|
|
|
|
07.04.26 - 13:33
|
Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire EN)
|
|
|
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 25th Annual Needham Virtual Healthcare Conference, April 13 – 16, 2026. President and Chief Executive Officer Christopher U. Missling, PhD and his management team will present the Company scheduled at 1:30 PM (ET) on Tuesday, April 14th, 2026....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
